Buscar
Mostrando ítems 91-100 de 235
Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data From 9222 Chronic Heart Failure Patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry
(Willey Online Library, 2020-04-03)
[Abstract]
Aims.
We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all‐cause or cardiovascular death ...
In-Hospital Post-Operative Infection after Heart Transplantation: Epidemiology, Clinical Management, and Outcome
(Mary Ann Liebert, 2020-02-13)
[Abstract] Background: Infection is a major cause of morbidity and mortality after heart transplantation (HT). Little information about its importance in the immediate post-operative period is available. The aim of this ...
Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results
(Wiley, 2015-04-23)
[Abstract] We conducted an observational study of 30 heart transplant recipients with serum low-density lipoprotein cholesterol (LDL-c) >100 mg/dl despite previous statin therapy, who were treated with rosuvastatin 10 mg ...
Código shock cardiogénico 2023: documento de expertos para una organización multidisciplinaria que permita una atención de calidad
(Elsevier, 2022-11-18)
[Resumen] Pese a los esfuerzos realizados para mejorar la atención al shock cardiogénico (SC), incluyendo el desarrollo de dispositivos de asistencia circulatoria mecánica (ACM), su pronóstico continúa siendo desfavorable. ...
Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy
(Elsevier, 2022-02)
[Abstract] Objective: To investigate a potential association between beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Methods: In this real-world prospective registry ...
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world
(Wiley, 2019-05-27)
[Abstract] Aims: To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines Agency/Food and Drug ...
Atlas of the clinical genetics of human dilated cardiomyopathy
(Oxford para European Society of Cardiology, 2014-08-27)
[Abstract] Aim. Numerous genes are known to cause dilated cardiomyopathy (DCM). However, until now technological limitations have hindered elucidation of the contribution of all clinically relevant disease genes to DCM ...
Prognostic Implications of Pathogenic Truncating Variants in the TTN Gene
(Elsevier, 2020-05-01)
[Abstract]
Introduction and objectives: TTN gene truncating variants (TTNtv) are a frequent cause of dilated cardiomyopathy
(DCM). However, there are discrepant data on the associated prognosis. Our objectives were to ...
In-hospital postoperative infection after heart transplantation: risk factors and development of a novel predictive score
(Wiley, 2019-05-11)
[Abstract] Introduction: Infection is one of the most significant complications following heart transplantation (HT). The aim of this study was to identify specific risk factors for early postoperative infections in HT ...
Risk Predictors in a Spanish Cohort With Cardiac Laminopathies. The REDLAMINA Registry
(Elsevier, 2020-06-29)
[Abstract]
Introduction and objectives.
According to sudden cardiac death guidelines, an implantable cardioverter-defibrillator (ICD) should be considered in patients with LMNA-related dilated cardiomyopathy (DCM) and ...